209 related articles for article (PubMed ID: 37748491)
1. CAR T-cell therapy in autoimmune diseases.
Schett G; Mackensen A; Mougiakakos D
Lancet; 2023 Nov; 402(10416):2034-2044. PubMed ID: 37748491
[TBL] [Abstract][Full Text] [Related]
2. Chimeric antigen receptor T cell therapy: a new emerging landscape in autoimmune rheumatic diseases.
Lyu X; Gupta L; Tholouli E; Chinoy H
Rheumatology (Oxford); 2024 May; 63(5):1206-1216. PubMed ID: 37982747
[TBL] [Abstract][Full Text] [Related]
3. Autologous CD19-Targeted Chimeric Antigen Receptor (CAR)T-Cells as the Future of Systemic Lupus Erythematosus Treatment.
Kambayana G; Surya Rini S
Curr Rheumatol Rev; 2023 Jun; 19(3):260-269. PubMed ID: 36786138
[TBL] [Abstract][Full Text] [Related]
4. CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated With Antisynthetase Syndrome.
Pecher AC; Hensen L; Klein R; Schairer R; Lutz K; Atar D; Seitz C; Stanger A; Schneider J; Braun C; Schmidt M; Horger M; Bornemann A; Faul C; Bethge W; Henes J; Lengerke C
JAMA; 2023 Jun; 329(24):2154-2162. PubMed ID: 37367976
[TBL] [Abstract][Full Text] [Related]
5. In vitro elimination of autoreactive B cells from rheumatoid arthritis patients by universal chimeric antigen receptor T cells.
Zhang B; Wang Y; Yuan Y; Sun J; Liu L; Huang D; Hu J; Wang M; Li S; Song W; Chen H; Zhou D; Zhang X
Ann Rheum Dis; 2021 Feb; 80(2):176-184. PubMed ID: 32998865
[TBL] [Abstract][Full Text] [Related]
6. CAR T cells for treating autoimmune diseases.
Blache U; Tretbar S; Koehl U; Mougiakakos D; Fricke S
RMD Open; 2023 Nov; 9(4):. PubMed ID: 37996128
[TBL] [Abstract][Full Text] [Related]
7. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus.
Mackensen A; Müller F; Mougiakakos D; Böltz S; Wilhelm A; Aigner M; Völkl S; Simon D; Kleyer A; Munoz L; Kretschmann S; Kharboutli S; Gary R; Reimann H; Rösler W; Uderhardt S; Bang H; Herrmann M; Ekici AB; Buettner C; Habenicht KM; Winkler TH; Krönke G; Schett G
Nat Med; 2022 Oct; 28(10):2124-2132. PubMed ID: 36109639
[TBL] [Abstract][Full Text] [Related]
8. CAR T-Cell Therapy in Autoimmune Disease.
Howard JF; Vu T; Mozaffar T
N Engl J Med; 2024 May; 390(17):1629-1631. PubMed ID: 38692299
[No Abstract] [Full Text] [Related]
9. CAR T-Cell Therapy in Autoimmune Disease.
Merkt W; Lorenz HM; Schmitt M
N Engl J Med; 2024 May; 390(17):1628-1629. PubMed ID: 38692297
[No Abstract] [Full Text] [Related]
10. CAR T-Cell Therapy in Autoimmune Disease.
De Benedetti F; Diomedi Camassei F; Locatelli F
N Engl J Med; 2024 May; 390(17):1629. PubMed ID: 38692298
[No Abstract] [Full Text] [Related]
11. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus.
Kansal R; Richardson N; Neeli I; Khawaja S; Chamberlain D; Ghani M; Ghani QU; Balazs L; Beranova-Giorgianni S; Giorgianni F; Kochenderfer JN; Marion T; Albritton LM; Radic M
Sci Transl Med; 2019 Mar; 11(482):. PubMed ID: 30842314
[TBL] [Abstract][Full Text] [Related]
12. Is There a Place for Chimeric Antigen Receptor-T Cells in the Treatment of Chronic Autoimmune Rheumatic Diseases?
Orvain C; Boulch M; Bousso P; Allanore Y; Avouac J
Arthritis Rheumatol; 2021 Nov; 73(11):1954-1965. PubMed ID: 34042325
[TBL] [Abstract][Full Text] [Related]
13. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
Schultz L
Front Immunol; 2020; 11():1985. PubMed ID: 32849662
[TBL] [Abstract][Full Text] [Related]
14. Chimeric Antigen Receptor Based Therapy as a Potential Approach in Autoimmune Diseases: How Close Are We to the Treatment?
Sadeqi Nezhad M; Seifalian A; Bagheri N; Yaghoubi S; Karimi MH; Adbollahpour-Alitappeh M
Front Immunol; 2020; 11():603237. PubMed ID: 33324420
[TBL] [Abstract][Full Text] [Related]
15. Prospects for CAR T cell immunotherapy in autoimmune diseases: clues from Lupus.
Radic M; Neeli I; Marion T
Expert Opin Biol Ther; 2022 Apr; 22(4):499-507. PubMed ID: 35089116
[TBL] [Abstract][Full Text] [Related]
16. B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases.
Haghikia A; Schett G; Mougiakakos D
Lancet Neurol; 2024 Jun; 23(6):615-624. PubMed ID: 38760099
[TBL] [Abstract][Full Text] [Related]
17. In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.
Ramos CA; Rouce R; Robertson CS; Reyna A; Narala N; Vyas G; Mehta B; Zhang H; Dakhova O; Carrum G; Kamble RT; Gee AP; Mei Z; Wu MF; Liu H; Grilley B; Rooney CM; Heslop HE; Brenner MK; Savoldo B; Dotti G
Mol Ther; 2018 Dec; 26(12):2727-2737. PubMed ID: 30309819
[TBL] [Abstract][Full Text] [Related]
18. Bispecific CAR T-cells for B-cell Malignancies.
Furqan F; Shah NN
Expert Opin Biol Ther; 2022 Aug; 22(8):1005-1015. PubMed ID: 35653589
[TBL] [Abstract][Full Text] [Related]
19. Dawn of CAR-T cell therapy in autoimmune diseases.
Liu Y; Dong M; Chu Y; Zhou L; You Y; Pang X; Yang S; Zhang L; Chen L; Zhu L; Xiao J; Wang W; Qin C; Tian D
Chin Med J (Engl); 2024 May; 137(10):1140-1150. PubMed ID: 38613216
[TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen receptors: "CARs" in the fast lane for rheumatology.
Johnson NM; Koumpouras F
Curr Opin Rheumatol; 2024 May; 36(3):176-183. PubMed ID: 38517338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
